Menu
News > General > Consistent survival benefit with ribociclib in the firstline treatment of pre- of perimenopausal women with HR+/HER2-advanced breast cancer

Consistent survival benefit with ribociclib in the firstline treatment of pre- of perimenopausal women with HR+/HER2-advanced breast cancer

February 2021 General Ariez

FDG PET/CT: complete metabolic response.
.
Top